AbbVie presented new data at the 2026 ASCO Annual Meeting showcasing its oncology pipeline targeting solid tumors and blood cancers. Key findings include promising results from antibody-drug conjugates (ADCs) and T-cell engagers in cancers like metastatic prostate, small cell lung, ovarian, and multiple myeloma. These therapies showed significant response rates and manageable safety profiles in early trials, highlighting AbbVie's innovative approach to cancer treatment. Further clinical data and studies will continue to evaluate these investigational medicines' potential.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
